Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration

Bibliographys

• HENDERSON BW, DOUGHERTY TJ: How does photodynamic therapy work. Photochem. Photobiol (1992) 55:145–157.
   PubMed Web of Science ®Google Scholar
• •A well written review of the principals of PDT for disease treatment.
   Google Scholar
• MESSMER KJ, ABEL SR: Verteporfin for age-related macular degeneration. Ann. Pharmacother. (2001) 35:1593–1598.
   PubMed Web of Science ®Google Scholar
• WOODBURN KW, ENGELMAN CJ, BLUMENKRANZ MS: Photodynamic therapy for choroidal neovascularization. A review. Ref-Ma (2002) 22:391–405.
   Google Scholar
• •A concise and well organised paper, discussing the principles of PDT, as applied to retinal disease, and reviews the chemistry of various photosensitive entities and their potential use in ophthalmic practice with an emphasis on verteporfin.
   Google Scholar
• HALKIOTIS K, YOVA D, PANTELIAS G: In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy. Mutagenesis (1999) 14:193–219.
   PubMed Web of Science ®Google Scholar
• WACHTLIN J, BLASIG IE, SCHRUNDER S, LANGENBECK K, HOFFMANN F: PRK and LASIK - their potential risk of cataractogenesis: lipid perwddation changes in the aqueous humor and crystalline lens of rabbits. Cornea (2000) 19:75–79.
   PubMed Web of Science ®Google Scholar
• VINGERLING JR, DIELEMANS I, HOFMAN A et al.: The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology (1995) 102:205–210.
   PubMed Web of Science ®Google Scholar
• FINE SL, BERGER JW, MAGUIRE MG, HO AC: Age-related macular degeneration. N Engl. J. Med. (2000) 342:483–492.
   PubMed Web of Science ®Google Scholar
• AMBATI J, AMBATI BK, Y00 SH, IANCHULEV S, ADAMIS AP: Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol (2003) 48:257–293.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of AMD.
   Google Scholar
• NO AUTHORS LISTED: Macular Photocoagualtion Study Group: Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch. Ophthalmol (1991) 109:1109–1114.
   PubMed Web of Science ®Google Scholar
• KVANTA A, ALGVERE PV, BERGLIN L, SEREGARD S: Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol Vis. Sci. (1996) 37:1929–1934.
   PubMed Web of Science ®Google Scholar
• OHNO-MATSUI K, MORITA I, TOMBRAN-TINK J et al.: Novel mechanism for age related macular degeneration: an equilibrium shift between angiogenesis factors VEGF and PEDF.J. Cell. Physiol (2001) 189:323–333.
   PubMed Web of Science ®Google Scholar
• SPRAUL CW, LANG GE, GROSSNIKLAUS HE, LANG GK: Histologic and morphometric analysis of the choroid, Bruch's membrane and retinal pigment epithelium in post-mortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv. Ophthalmol (1999) 44\(Suppl. 1):S10–S32.
   Google Scholar
• NO AUTHORS LISTED: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials-tap report 1. Arch. Ophthalmol (1999) 117:1329–1345.
   PubMed Web of Science ®Google Scholar
• •The first of a series of clinical reports summarising details of therapeutic results and safety of verteportin for AMD.
   Google Scholar
• NO AUTHORS LISTED: Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocogaulation study. The Macular Photocoagulation Study Group. Arch. Ophthalmol (1991) 109:1242–1257.
   Google Scholar
• NO AUTHORS LISTED: Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascular lesions. Results of a randomized clinical trial. Arch. Ophthalmol (1990) 108:816–824.
   Google Scholar
• NO AUTHORS LISTED: Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascular lesions. Results of a randomized clinical trial. Arch. Ophthalmol (1990) 108:832–837.
   Google Scholar
• NO AUTHORS LISTED: Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch. OphthahnoL (1991) 109:1220–1231.
   Google Scholar
• NO AUTHORS LISTED: Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol (1991) 109:1232–1241.
   Google Scholar
• NO AUTHORS LISTED: Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch. OphthahnoL (1993) 111:1200–1209.
   Google Scholar
• MILLER G, MILLER B: Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch. Ophthalmol (1993) 111:855–860.
   PubMed Web of Science ®Google Scholar
• MILLER JW, WALSH AW, KRAMER M et al.: Photodynamic therapy of experimental neovascularization using lipoprotein-delivered benzoporphyrin. Arch. Ophthalmol (1995) 113:810–818.
   PubMed Web of Science ®Google Scholar
• HUSAIN D, MILLER JW, MICHAUD N, CONNOLLY E, FLOTTE TJ, GRAGOUDAS ES: Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch. Ophthalmol (1996) 114:978–985.
   PubMed Web of Science ®Google Scholar
• COHEN SY, BULIK A, DUBOIS L, QUENTEL G: Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am. Ophthalmol (2003) 136:371–374.
   PubMed Web of Science ®Google Scholar
• BUSQUETS MA, SHAH GK, WICKENS J et al.: Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina (2003) 23(3):299–306.
   PubMed Web of Science ®Google Scholar
• BLINDER KJ, BRADLEY S, BRESSLER NM et al.: Effect of lesion size, visual acuity and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am. J. Ophthalrnol (2003) 136:407–418.
   Google Scholar
• •• Pivotal study discussing enhanced optionsfor verteporfin in AMD, in terms of lesion size and classification, and safety.
   Google Scholar
• MILLER JW, WALSH AW, KRAMER M: Photodynamic therapy of experimental choroidal neovascularization using a lipoprotein delivered benzoporphyrin. Arch. Ophthalmol (1995) 113:810–818.
   PubMed Web of Science ®Google Scholar
• REINKE MH, CANAKIS C, HUSAIN D: Verteporfin photodynamic therapy retreatment of the normal retina and choroid in the cynomoglus monkey. Ophthalmology (1999) 106:1915–1923.
   PubMed Web of Science ®Google Scholar
• MILLER JW, SCHMIDT-ERFURTH U, SICKENBERG M et al: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a Phase I and 2 study. Arch. Ophthalmol (1999) 117:1161–1173.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ERFURTH U, MILLER JVV, SICKENBERG M et al: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of retreatments in a Phase I and II study. Arch. Ophthalmol (1999) 117:1177–1187.
   PubMed Web of Science ®Google Scholar
• •• This important clinical trial demonstratedthe visual benefits and safety of serial verteporfin treatment for AMD.
   Google Scholar
• BRESSLER NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP report 2. Arch. Ophthalmol (2001) 119:198–207.
   Google Scholar
• BLUMENKRANZ MS, BRESSLER NM, BRESSLER SB et al: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open label extension of 2 randomized clinical trials - TAP report No. 5. Arch. Ophthalmol (2002) 120:1307–1314.
   Google Scholar
• ••Discusses long-term vision outcomes andsafety of verteporfin use in AMD.
   Google Scholar
• NO AUTHORS LISTED: Verteporfin in Photodynamic therapy study group. Subfoveal neovascular lesions in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult and non-classic chorodial neovascularization. Verteporfin in Photodynamic therapy report 2. Am. J. Ophthalmol (2001) 131:541–560.
   Google Scholar
• ••Summarises the influence of lesion size and initial visual acuity on the result of verteporfin treatment for AMD.
   Google Scholar
• BRESSLER NM, ARNOLD J, BENCHABOUNE M et al: Verteporfin therapy of subfoveal choroidal neovascularization in patients with age related macular degeneration. Additional information regarding baseline lesion composition's impact on vision outcomes - TAP Report No. 3. Arch. Ophthalmol (2002) 120:1443–1454.
   Google Scholar
• ••Demonstrates that use of nutritionalanti-oxidant supplements or laser photocoagulation does not affect the visual outcome of verteporfin therapy for AMD.
   Google Scholar
• HOSKIN A, BIRD AC, SEHMI K: Tears of the detached retinal pigmented epithelium. Br. J. Ophthalmol (1981) 65:417–422.
   PubMed Web of Science ®Google Scholar
• GASS JD: Retinal pigment epithelial rip during krypton red laser photocoagulation. Am. Ophthalmol (1984) 98:700–706.
   PubMed Web of Science ®Google Scholar
• GELISKEN F, INHOFFEN W, PARTSCH M, SCHNEIDER U, KREISSIG I: Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularizatoin. Am. J. Ophthalmol (2001) 131:518–520.
   PubMed Web of Science ®Google Scholar
• PECE A, INTROINI U, BOTTONI F, BRANCATO R: Acute retinal pigment epithelial tear after photodynamic therapy. Retina (2001) 21:361–363.
   PubMedGoogle Scholar
• WACHTLIN J, BEHME T, HEIMANN H, KELLNER U, FOERSTER MH: Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch. Clin. Exp. Ophthalmol (2003) 241:518–521.
   PubMed Web of Science ®Google Scholar
• MANSOUR AM, HUSSEINI AM, SCHAKAL AR: Macular hole following photodynamic therapy. Ophthalmic Surg. Lasers (2002) 33:511–513.
   PubMedGoogle Scholar
• THEODOSSIADIS GP, PANAGIOTIDIS D, GEORGALAS IG, MOSCHOS M: Retinal hemorrhage after photodynamic therapy in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol (2003) 241:8–13.
   PubMedGoogle Scholar
• HOULE JM, STRONG HA: Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina (2002) 22:691-697. 359
   Google Scholar
• •Describes the kinetics and incidence of photosensitivity and photosensitvity reactions associated with verteporfin use.
   Google Scholar
• ITAGAKI T, MATSUYUKI D, SHIGEHITO S, SHIGERU K: Skin burn caused by operating light during a long operation after photodynamic therapy. Anesthesiology(2003) 98:1011–1013.
   PubMed Web of Science ®Google Scholar
• PACKAGE LABELING; VisudyneTm (verteporfin for injection), Novartis Ophthalmics Inc., Duluth, Georgia, USA. May 2002.
   Google Scholar
• BICKERS DR: Photosensitivity and other reactions to light. In: Harrison's Principles of Internal Medicine (13th edni. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci A, Kasper DL (Eds), McGraw-Hill, Inc., New York, USA (1994):307–312.
   Google Scholar
• LIN GC, TSOUKAS ML, LEE MS: Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy. Photochein. Photobiol (1998) 68:575–583.
   PubMed Web of Science ®Google Scholar
• DRUG INFORMATION HANDBOOK 2003: McEvoy GK (Ed.). American society of health system pharmacists, Inc, Bethesda, USA (2003):2725–2727.
   Google Scholar
• ••A comprehensive, widely utilised, referencetext, describing drugs currently approved for use within the US. Updated yearly.
   Google Scholar
• PHYSICIANS DESK REFERENCE (54th edn). Medical economics Co., Montvale, USA (2000):1368, 2345.
   Google Scholar
• TORNAMBE PE: Using intravenous diphenhydramine to minimize back pain associated with photodynamic therapy with Verteporfin. Arch. Ophthalinol (2002) 120:872–873.
   PubMed Web of Science ®Google Scholar
• •An informative study describing the outcome of prophylaxis for verteporfin-associated pain.
   Google Scholar
• BORODOKER N, SPAIDE RF, MARANAN L et al.: Verteporfin infusion-associated pain. Ain. J. Ophthalinol (2002) 133:211–214.
   Web of Science ®Google Scholar
• •Discusses the role of oral hydration in the prevention of verteporfin-associated pain.
   Google Scholar
• HUI YF, CORTES JE: Chest and back pain associated with a six-hour infusion of liposomal daunorubicin. Ann. Pharinacother. (2000) 34:810–811.
   PubMed Web of Science ®Google Scholar
• JOHNSON MD, DREW RH, PERFECT JR: Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharinacotherapy (1998) 18:1053–1061.
   PubMed Web of Science ®Google Scholar
• RODEN MM, NELSON LD, KNUDSON TA et al.: Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin. Infect. Dis. (2003) 36:1213–1220.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO K, SCHULTZ E, HEATH T, MITCHELL MD, ALBERTINE KH, STAUB NC: Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. Appl. Physic] (1988) 64:1143–1152.
   PubMed Web of Science ®Google Scholar
• SPAIDE RF, MARANAN L: Neuttophil margination as a possible mechanism for verteporfin infusion-associated pain. Am. J. Ophthalinol (2003) 135:549–550.
   PubMed Web of Science ®Google Scholar
• BERRIOS GE, BROOK P: The Charles Bonnet syndrome and the problem of visual perception disorders in the elderly. Age Ageing. (1982) 11:17–23.
   PubMed Web of Science ®Google Scholar
• COHEN SY, BULIK A, TADAYONI R,QUENTEL G: Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age-related macular degeneration. Br. J. Ophthalinol (2003) 87:977–979.
   PubMed Web of Science ®Google Scholar
• BROWN GC, MURPHY RP: Visual symptoms associated with choroidal neovascularization. Photopsia and the Charles Bonnet syndrome. Arch. Ophthalinol (1992) 110:1251–1256.
   PubMed Web of Science ®Google Scholar
• •An interesting discussion of various photopsia and visual hallucinations observed in retinal disease.
   Google Scholar
• COHEN SY, SAFRAN AB, TADAYONI R et al.: Visual hallucinations immediately after macular photocoagulaion. Am. J. Ophthalinol (2000) 129:815–816.
   PubMed Web of Science ®Google Scholar
• AU EONG K, FUJII GY, NG EW et al: Transient formed hallucinations following macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am. J. Ophthalinol (2001) 131:664–666.
   PubMed Web of Science ®Google Scholar
• KANG SW, KANG SJ, KIM OH, NAM ES, LEE JH, KOH HJ: Photodynamic therapy using verteporfin-induced minimal change nephrotic syndrome. Ain. .1. Ophthalinol (2002) 134:907–908.
   Web of Science ®Google Scholar
• SCHNAPER HW, ROBSON AM: Nephrotic syndrome: minimal change nephrotic syndrome, focal glomerulosclerosis and related disease. In: Diseases of the kidney Schrier RW, Gottschalk CW (Eds). Little, Brown and Company, Boston, USA (1993):1731–1784.
   Google Scholar
• FINKELSTEIN A, FRALEY DS, STACHURA I, FELDMAN HA, GANDY DR, BOURKE E: Fenoprofen nephropathy: lipoid nephrosis and interstitial nephritis. A possible T-lymphocyte disorder. Am. .1. Med. (1982) 72:81–87.
   Google Scholar
• HUNT DW, JIANG H, GRANVILLE DJ, CHAN AH, LEONG S, LEVY JG: Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. Immunopharmacology (1991) 41:31–44.
   Google Scholar
• ••A description of the immunomodulatoryaction of verteporfin in terms of the antigenic potential on circulating T cells.
   Google Scholar
• NOFFKE AS, JAMPOL LM, WEINBERG DV, MUNANA A: A potentially life-threatening adverse event reaction to verteporfin. Arch. Ophthalmol (2001) 119:143.
   PubMed Web of Science ®Google Scholar
• •A case report of an apparently isolated, yet potentially serious event related to verteporfin use.
   Google Scholar
• CAHILL MT, SMITH BT, FEKRAT S: Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (Visudyne). Am. J. Ophthalmol (2002) 134:281–282.
   PubMed Web of Science ®Google Scholar
• •A case scenario that all health care workers should be familiar with.
   Google Scholar
• MIMOUNI KF, BRESSLER SB, BRESSLER NM: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children. Am. J. Ophthalmol (2003) 135:900–902.
   PubMed Web of Science ®Google Scholar
• •The typical exclusion of children in both pre- and post-marketing clinical drug studies in the US, makes this article of particular interest.
   Google Scholar
• US FDA: Premarket approval package. Summary of safety and effectiveness for Visudyne (verteporfin for injection). PMA # p990048. Docket # 00M-1300. June 2000.
   Google Scholar
• KEMP JD: The role of iron binding proteins in lymphocyte physiology and pathology. Clin. Immunol (1993) 13:81–92.
   Web of Science ®Google Scholar
• HRYHORENKO E, RITTENHOUSE-DIAKUN K, HARVEY NS, MORGAN J, STEWART CC, OSEROFF AR: Characterization of endogenous protoporphyrin IX induced by amino-levulinic acid in resting and activated peripheral lymphocytes by four-color flow cytometry. Photochem. Photobiol (1998) 67:565-572. 360
   Google Scholar
• NO AUTHORS LISTED: Pediatric dosagehandbook (1 Oth edn). Taketomo CK, Hodding JH, Kraus DM (Eds), Lexi-Comp, Hudson Ohio, USA (2003):1283.
   Google Scholar
• REICH I, SCHNAARE RL, SUGITA ET: Pharmaceutical Calculations. In: Remington 's Pharmaceutical Sciences (20th edn). Gennaro AR, Der Marderosian AH, Hanson GH, Medwick T, Popovich NG, Schnaare RL, Schwartz JB, White HS (Eds), Williams and Wilkins, Baltimore, USA (2000):110–111.
   Google Scholar